Promising drug targets Tough-to-Treat leukemia in small trial
NCT ID NCT06648889
First seen Jan 20, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This study tests a drug called isatuximab in 40 adults with a rare and aggressive blood cancer (T-cell acute lymphoblastic leukemia, or T-ALL) that has returned or not responded to standard treatment. The drug targets a protein (CD38) on the cancer cells to help the immune system attack them. The goal is to see if it can shrink the cancer or clear it from the bone marrow, and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt Hämatologie
RECRUITINGBerlin, 12203, Germany
Contact
Contact
-
Goethe University Hospital Frankfurt, Department of Medicine, Hematology and Oncology
RECRUITINGFrankfurt am Main, 60580, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I
RECRUITINGDresden, 01307, Germany
Contact
Contact
-
Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin - Onkologie und Hämatologie
RECRUITINGOldenburg, 26135, Germany
Contact
Contact
-
Robert-Bosch-Krankenhaus; Abteilung für Hämatologie, Onkologie und Palliativmedizin
RECRUITINGStuttgart, 70376, Germany
Contact
Contact
-
University Hospital Augsburg, II. Medizinischen Klinik, Hämatologie, internistische Onkologie und Hämostaseologie
RECRUITINGAugsburg, 86156, Germany
Contact
Contact
-
University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology
RECRUITINGDüsseldorf, 40225, Germany
Contact
Contact
-
University Hospital Erlangen AöR, Department of Medicine 5
RECRUITINGErlangen, 91054, Germany
Contact
Contact
-
University Hospital Hamburg-Eppendorf, Department of Medicine II
RECRUITINGHamburg, 20251, Germany
Contact
Contact
-
University Hospital Heidelberg, Department V, Hematology, Oncology and Rheumatology
RECRUITINGHeidelberg, 69120, Germany
Contact
Contact
-
University Hospital Leipzig; Klinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Bereich Hämatologie und Zelltherapie
RECRUITINGLeipzig, 04103, Germany
Contact
Contact
-
University Hospital München-Großhadern, Medizinische Klinik und Poliklinik III
RECRUITINGMünchen, 81377, Germany
Contact
Contact
-
University Hospital Münster, Medizinische Klinik A / KMT-Zentrum
RECRUITINGMünster, 48149, Germany
Contact
Contact
-
University Hospital Schleswig-Holstein, Campus Kiel, Medical Department II
RECRUITINGKiel, 24105, Germany
Contact
Contact
Conditions
Explore the condition pages connected to this study.